Spravato ketamine
Selected indexed studies
- Pharmacotherapy: Ketamine and Esketamine. (Psychiatr Clin North Am, 2023) [PMID:37149345]
- Long-term safety of ketamine and esketamine in treatment of depression. (Expert Opin Drug Saf, 2022) [PMID:35416105]
- Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. (J Affect Disord, 2021) [PMID:33022440]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis. (2024) pubmed
- Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations. (2025) pubmed
- Pharmacotherapy: Ketamine and Esketamine. (2023) pubmed
- Long-term safety of ketamine and esketamine in treatment of depression. (2022) pubmed
- Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. (2021) pubmed
- Personalized use of ketamine and esketamine for treatment-resistant depression. (2024) pubmed
- Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. (2022) pubmed
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. (2019) pubmed
- The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials. (2024) pubmed
- Esketamine: Less Drowsiness, More Analgesia. (2024) pubmed